• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $UPB

    Upstream Bio Inc.

    Subscribe to $UPB
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2024

    Exchange: NASDAQ

    Recent Analyst Ratings for Upstream Bio Inc.

    DatePrice TargetRatingAnalyst
    11/5/2024$75.00Overweight
    Piper Sandler
    11/5/2024$38.00Overweight
    JP Morgan
    11/5/2024Outperform
    William Blair
    11/5/2024Buy
    TD Cowen
    See more ratings

    Upstream Bio Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

      Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

      7/21/25 7:00:00 AM ET
      $BBNX
      $BCAX
      $KMTS
      $MORF
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

      – Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthening pipeline across severe respiratory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and COPD – – Program updates also include completion of enrollment in Phase 2 clinical trial in severe asthma; top-line data now expected in first quarter of 2026 – WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an in

      7/8/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

      – Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) – WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the presentation of translationa

      6/15/25 7:45:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

      WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced an upcoming presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK, on Sunday, June 15, 2025. The presentation features translational pharmacology modeling data that supports Thymic Stromal Lymphopoietin (TSLP) receptor targeting with verekitug as a mechanism for greater potency when compared to treatment approaches that target the TSLP ligand. Presentation details: Presentation Title: In silico system pharmac

      6/5/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

      WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025, at 9:20 a.m. ET. A live webcast of the fireside chat will be available under the "Events" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be posted on the Company's website following the presentation. About Upst

      6/4/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Appoints Stacy Price as Chief Technology Officer

      WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

      5/20/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

      – Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to be dosed in mid-2025 – WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the first quarter ended Mar

      5/6/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      – Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a summary of recent business highlights. Upstream is developing verekitug, the only monoclonal

      3/12/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio to Present at Upcoming March Investor Conferences

      WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Upstream Bio's CEO, will present at the following upcoming March investor conferences: TD Cowen 45th Annual Health Care Conference, Boston MATuesday, March 4, 2025, 11:50 a.m. – 12:20 p.m. ET Leerink Partners Global Biopharma Conference 2025, Miami FLWednesday, March 12, 2025, 1:40 p.m. – 2:10 p.m. ET A live webcast of the presentation will be available under the "Events" tab on the "Investors" page of the Company's website on the day of

      2/25/25 8:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps

      Upstream's 2025 Automotive & Smart Mobility Cybersecurity Report reveals that 60% of cyber incidents could affect thousands to millions of connected vehicles, with massive-scale attacks more than tripling; the report emphasizes that current regulatory requirements are insufficient to address expanding cyber risks. ANN ARBOR, Mich., Feb. 11, 2025 /PRNewswire/ -- Upstream Security, the leading provider of cloud-based cybersecurity and data management platform purpose-built for automotive, smart mobility, and IoT ecosystem, today released the 2025 Automotive & Smart Mobility Cybersecurity Report. The annual report, returning for its seventh year, highlights that despite the increased regulatory

      2/11/25 9:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Upstream Bio Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Upstream Bio with a new price target

      Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00

      11/5/24 6:29:20 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Upstream Bio with a new price target

      JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00

      11/5/24 6:28:28 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Upstream Bio

      William Blair initiated coverage of Upstream Bio with a rating of Outperform

      11/5/24 6:28:02 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Upstream Bio

      TD Cowen initiated coverage of Upstream Bio with a rating of Buy

      11/5/24 6:27:10 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Upstream Bio Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chimovits Erez bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:19:30 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:17:52 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Ai Upstream Llc bought $19,975,000 worth of shares (1,175,000 units at $17.00) and converted options into 4,319,410 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:05:04 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Upstream Bio Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Renaud Ronald C Jr

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:33 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ruddy Marcella K.

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:30 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chimovits Erez

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:31 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fleming Harold Edward

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:21 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Beckman Daniella

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:29 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ratcliffe Liam

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:20 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Sutherland Everett Rand

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      2/7/25 5:32:21 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO and COO Gray Michael

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      2/7/25 5:31:01 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Business Officer Houghton Adam

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      2/7/25 5:29:56 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Deykin Aaron

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      2/7/25 5:29:21 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Upstream Bio Inc. SEC Filings

    See more
    • Upstream Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Upstream Bio, Inc. (0002022626) (Filer)

      6/12/25 4:18:05 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Upstream Bio Inc.

      10-Q - Upstream Bio, Inc. (0002022626) (Filer)

      5/6/25 7:10:23 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Upstream Bio, Inc. (0002022626) (Filer)

      5/6/25 7:05:10 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Upstream Bio Inc.

      DEFA14A - Upstream Bio, Inc. (0002022626) (Filer)

      4/17/25 4:10:03 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Upstream Bio Inc.

      DEF 14A - Upstream Bio, Inc. (0002022626) (Filer)

      4/17/25 4:05:05 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Upstream Bio Inc.

      S-8 - Upstream Bio, Inc. (0002022626) (Filer)

      3/12/25 7:15:34 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Upstream Bio Inc.

      10-K - Upstream Bio, Inc. (0002022626) (Filer)

      3/12/25 7:10:34 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Upstream Bio, Inc. (0002022626) (Filer)

      3/12/25 7:05:08 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Upstream Bio Inc.

      SCHEDULE 13G - Upstream Bio, Inc. (0002022626) (Subject)

      2/14/25 5:38:41 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Upstream Bio Inc.

      SCHEDULE 13G - Upstream Bio, Inc. (0002022626) (Subject)

      2/14/25 4:23:29 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Upstream Bio Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Upstream Bio Appoints Stacy Price as Chief Technology Officer

      WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

      5/20/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Appoints Allison Ambrose as General Counsel

      WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to

      12/17/24 8:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Upstream Bio Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upstream Bio Inc.

      SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

      11/7/24 9:24:55 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Upstream Bio Inc.

      SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

      10/22/24 4:06:27 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Upstream Bio Inc.

      SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

      10/18/24 6:10:56 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Upstream Bio Inc.

      SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

      10/17/24 4:16:24 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care